记者丨 闫硕 编辑丨季媛媛 创新药 "黑马" 舒泰神，主力产品卖不动、5年亏超10亿，凭啥股价半年涨600%？ 今年以来，创新药迎来新一轮增长。二级市场上，截至8月27日收盘， 创新药企舒泰神作为一匹"黑马"，从年初至今股价涨幅已超6倍。 不 过，与之相对应的是，其上半年业绩依旧承压，尚未扭亏为盈。 | 50.85 -2.15 -4.06% | | | | | | 部泰神 立即 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 300204 交易 | | SZSE CNY 10:40:03 交易中 | | | | | | 疑似减持受限公 ○ 十 | | 委比 | 55.67% 委差 | 108 | | Wind ESG评级 3 | | 详情 | | 卖五 | 50.92 | | 6 交生 | 586.23% 120日 | | 578.91% | | 卖四 | 50.88 | | 5 2日 | -4.97% 250日 | | 601.38% | | 卖三 | 50.87 | | 5 20日 | -2.19% 52周高 | | 66.66 | ...

Core Viewpoint - The innovative pharmaceutical company Shuyou Shen has experienced significant stock price growth in 2024, despite facing ongoing financial losses and declining revenues in its recent performance report [1][2]. Financial Performance - In the first half of 2025, Shuyou Shen reported revenue of 126 million yuan, a year-on-year decrease of 31.14% [1]. - The company recorded a net profit attributable to shareholders of -24.64 million yuan, a substantial decline of 619.70% year-on-year [1]. - The basic loss per share was 0.05 yuan, continuing a trend of declining revenues and profits since 2018, with total losses exceeding 1 billion yuan since 2020 [1][2]. Product Sales - The main products, Sutai Sheng and Shuyou Qing, saw disappointing sales in the first half of 2025, with Sutai Sheng generating 74.32 million yuan (59.17% of revenue) and Shuyou Qing generating 41.69 million yuan (33.19% of revenue), both showing declines of 5.71% and 57.88% respectively [2][3]. - The decline in sales is attributed to external environmental factors and industry policy changes, particularly affecting Shuyou Qing due to its exclusion from the latest national procurement list [2][3]. Research and Development - Shuyou Shen is focusing on product iteration and accelerating the launch of its research pipeline to address performance challenges [2][3]. - The company has launched new products targeting constipation and bowel cleansing, and is advancing the clinical development of STSP-0902, a fourth-generation product related to Sutai Sheng [2][3]. - The company is also advancing several research projects, including STSP-0601, which has received breakthrough therapy designation and is aimed at treating hemophilia patients [3][4]. Stock Performance - Shuyou Shen's stock price has surged over 600% since December 31, 2024, driven by positive news regarding its research products, particularly STSP-0601 [4]. - Despite the stock's impressive performance, market analysts caution about potential pullback risks due to overall market weakness and the stock nearing pressure levels [4]. Funding and Investment - The company has seen a significant increase in net cash flow from financing activities, which rose by 1347.91% to 189 million yuan, primarily due to investments from the Jin Yi Yuan Li Fund [5]. - The fund's investment is directed towards Shuyou Shen's subsidiary, Jiangsu Beijietai Biotechnology Co., which is responsible for advancing STSP-0601 [5][6].

Core Viewpoint - Shuyou Shen is gaining market attention as an innovative drug development and commercialization company, focusing on clinical value and advancing its pipeline projects through strategic partnerships and external capital infusion [1][2]. Group 1: Company Strategy and Developments - The establishment of the subsidiary Beijietai in Wuxi is aimed at leveraging the favorable business environment and support for biopharmaceutical innovation [1][2]. - Shuyou Shen has received a total of 200 million yuan from the Jin Yi Yuan Li Fund for capital increase and equity transfer, indicating strong external investment interest [1]. - The company is committed to a strategy of innovation-driven development, focusing on differentiated competition and advancing drug commercialization [1][2]. Group 2: R&D Focus and Pipeline - Shuyou Shen is concentrating resources on clinical-stage projects with clear commercialization potential, particularly in areas such as neurological diseases, respiratory and critical care, infectious diseases, and autoimmune diseases [4]. - The company has multiple projects in clinical trials, with STSA-1002 and BDB-001 nearing completion of Phase II trials, and BDB-001 recognized as a breakthrough therapy by the National Medical Products Administration in 2023 [4]. - The company is also exploring the application of artificial intelligence in drug development to enhance efficiency and reduce costs [5][6]. Group 3: Market Position and Product Offerings - Shuyou Shen's main marketed products include innovative biopharmaceuticals such as Su Tai Sheng (injection of mouse nerve growth factor) and Shuyai Qing (compound polyethylene glycol electrolyte solution) [6]. - The company is actively iterating on its existing products, with new formulations launched since 2022 to improve patient compliance and accessibility [6].

Core Viewpoint - Shuyou Shen (300204) has been dubbed the "king of A-share gains" in innovative drugs, with a nearly 500% increase in stock price over two months, driven by the progress of three innovative drugs, including the acceptance of the listing application for STSP-0601 by the National Medical Products Administration [1][4][10] Stock Performance - On June 17, Shuyou Shen's stock price opened at 39.1 yuan per share, peaked at 43.15 yuan, and ultimately closed at 35.75 yuan, down 8.33% for the day, with a trading volume of 2.27 billion yuan and a turnover rate of 12.27% [3][4] - The stock has seen a cumulative increase of 470.18% from April 8 to June 17, making it the top performer in the A-share innovative drug sector [4][10] Institutional Involvement - Recent trading data indicates that institutional investors and speculative funds have been the primary drivers behind the stock's price surge, with institutions net buying approximately 211 million yuan from May 27 to June 9 [4][10] New Drug Developments - Shuyou Shen is focused on developing therapeutic drugs for unmet clinical needs, with a particular emphasis on protein drugs and chemical drugs targeting infectious diseases, respiratory and critical illnesses, autoimmune diseases, and neurological disorders [6][10] - The most notable drug in development is STSP-0601, which has received a registration application acceptance notice from the National Medical Products Administration, aimed at treating bleeding in adult patients with hemophilia A or B [6][7][8] Financial Performance - The company has reported net losses for five consecutive years, with revenues declining from 4.25 billion yuan in 2020 to 3.25 billion yuan in 2024, and corresponding net losses increasing from -1.33 billion yuan to -1.45 billion yuan [10][11] - In Q1 of this year, the company reported revenues of approximately 63.21 million yuan, a year-on-year decrease of 33.45%, while the net loss was reduced to -2.335 million yuan [10][11] Market Outlook - Analysts suggest that the future direction for innovative drug companies should focus on diversification and innovation, emphasizing the importance of R&D investment and market strategy adjustments [12] - Shuyou Shen has indicated plans to utilize various financing methods to alleviate short-term pressures while continuing its commitment to innovative drug development [12]

近期，港、A两市的创新药概念持续爆发，信达生物（01801.HK）、荣昌生物（09995.HK）、三生国 健（688336.SH）、科兴制药（688136.HK）、舒泰神（300204.SZ）等多股迎来大涨。 其中，于5月20日至6月3日期间，舒泰神的股价累涨超过188%，走势异常强劲。不过，6月4日，舒泰神 出现回调，其股价一度跌逾8%。 板块狂飙，叠加利好消息 舒泰神在近期迎来暴涨其实受到了多方面的刺激。 从板块走势来看，今年以来，港、A两市的创新药板块本身走势就比较强劲，港股市场的生物医药B类 股指数累涨逾80%，创新药概念指数累涨逾40%；A股市场的创新药概念亦涨超20%。 机构如何看待创新药后市？ 值得注意的是，虽然创新药概念已经涨了不少，但还有许多机构依然看好板块前景。 而在近期，创新药板块还接连迎来利好消息，这进一步刺激了创新药行情的走强。例如，5月国内有多 款创新药获批上市；还有三生制药（01530.HK）和辉瑞（PFE.US）签署授权协议，12.5亿美元首付 款，刷新了国产创新药出海的首付款记录；中国创新药企闪耀ASCO，共有71项原创性研究成果入选口 头发言环节等。 在板块普涨的因素之外， ...